Supernus Pharmaceuticals (SUPN) exceeded Q3 earnings and revenue estimates, but future performance outlook is negative.

From NASDAQ.: 2024-11-04 19:35:03

Supernus Pharmaceuticals (SUPN) reported quarterly earnings of $1.06 per share, surpassing expectations by 171.79%. The company’s revenues for the quarter were $175.69 million, beating estimates by 13.30%. Supernus shares have increased by 17.4% this year. Analysts are cautious about the stock’s future performance due to unfavorable estimate revisions, giving it a Zacks Rank #4 (Sell).

Amphastar Pharmaceuticals (AMPH) is set to announce its quarterly results on November 6. Analysts expect earnings of $1.03 per share, down 10.4% year-over-year. Revenue is projected to be $195.81 million, an 8.5% increase from the previous year. The company’s consensus EPS estimate for the quarter has been revised 1.3% lower.

Research Chief names a stock with the potential to double in value, targeting millennial and Gen Z audiences. The company generated nearly $1 billion in revenue last quarter. Investors are encouraged to explore this opportunity amidst a recent pullback in the stock. To access more stock recommendations, investors can visit Zacks Investment Research for insights and analysis.



Read more at NASDAQ.: Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates